10 results about "Hypnotic agent" patented technology

This disclosure relates to a method tapering or uptitrating a drug, e.g., benzodiazepines or non-benzodiazepine sedative hypnotics. Also disclosed is an apparatus for cutting or splitting a pill which can be used to blind or mask a dosage during a taper or uptitration plan. Also disclosed are methods of using the apparatus.

Methods and compositions for the treatment of conditions associated with pharyngeal airway muscle collapse while the subject is in a non-fully conscious state, e.g., sleep apnea and snoring, comprising administration of (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a non myorelaxing hypnotic and / or 5-HT2A inverse agonist or antagonist.

The application belongs to the field of electrochemical synthesis, and discloses a method for preparing indane compounds under electrochemical conditions. The method uses inexpensive nickel as a catalyst to realize the cycloaddition reaction of 1,6-diynyl and alkyne under electrolytic conditions at room temperature, and rapidly and efficiently synthesizes indane compounds. The method can be applied to the cycloaddition reaction of 1,6-diynyl derived from the barbituric acid, a sedative and hypnotic, and 2,6-dichloro-5-fluoronicotinic acid ethyl ester, a medical intermediate, and synthesizes indane compounds containing a pharmacologically active fragment. The method has green and mild reaction conditions, does not need heating and uses a noble metal catalyst, has low reaction cost, and has good application value.

Methods and compositions for the treatment of conditions associated with pharyngeal airway muscle collapse while the subject is in a non-fully conscious state, e.g., sleep apnea and snoring, comprising administration of (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a non myorelaxing hypnotic and / or 5-HT2A inverse agonist or antagonist.

The invention relates to administration of clinical anesthesia. Particular embodiments provide systems and methods for controlled delivery of a combination of an analgesic agent and a hypnotic agent. More specifically, the invention relates to closed-loop control systems / methods for automatically controlling the administration of a combination of a hypnotic agent and an analgesic agent in a clinical anesthesia setting which incorporate feedback based on one or more indirect measures / indicia of analgesia. The invention further relates to such control systems / methods that account for limitations of such indirect measures / indicia of analgesia.

The application belongs to the field of pharmacy, discloses a fused ring morphine derivative and a preparation method and application thereof, and relates to N-cyclopropylmethyl-4'-substituted aminonalepotem series derivatives with formula (I) and pharmaceutically acceptable salts. The derivative with formula (I) is prepared by reacting thebaine with a substituted phenyl vinyl ketone reagent and through a series of conversion methods. Among them, N-cyclopropylmethyl-(4'-benzoyl amino) nalepotem (SLL-1062) is a typical high selectivity mu opioid receptor antagonist, and can be applied to the research and development in the fields of diagnosis and treatment of opioid and other narcotic analgesic dependence, opioid drug-induced intestinal dysfunction, sedative hypnotics and acute alcohol poisoning, opioid and other narcotic analgesic poisoning and the like.

Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I):wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.

Provided herein are methods of treating sleep apnea in a subject, the method comprising: identifying a subject as having sleep apnea; and administering to the subject an effective amount of a carbonic anhydrase inhibitor and nonbenzodiazepine sedative-hypnotic, optionally including a selective serotonin-norepinephrine reuptake inhibitor.

Method for controlling the hypnotic and analgesic concentration of anesthetic compositions, the method comprising the steps of: providing a memory unit configured to receive and record data; providing at least one data processing unit (101) in signal communication with the memory unit and configured to process data and record the same in the memory unit; providing a patient treated with a first anesthetic composition comprising an initial hypnotic concentration and an initial analgesic concentration, and recording the patient's bispectral index (P BIS ) and mean arterial pressure (P MAP ), and storing the patient's P BIS and P MAP data in the memory unit, the method being characterized in that it further comprises the steps of: providing a two-dimensional matrix defined on the abscissa by a MAP dimension varying with respect to the mean arterial pressure and on the ordinate by a BIS dimension varying with respect to the bispectral index; defining in the matrix an optimal anesthesia zone (OAZ) located at MAP values of 65 to 110 mmHg and BIS values of 40 to 60; locating in the matrix the values of P BIS and P MAP data to define in the matrix the patient's position (B) with respect to the optimal anesthesia zone (OAZ); providing an algorithm resident in the processing unit configured to quantify the deviation of the patient's position (B) with respect to the optimal anesthesia zone (OAZ) and transform the deviation into a quantitative change in the initial hypnotic concentration and / or the initial analgesic concentration of the first anesthetic composition to define a target hypnotic concentration and / or a target analgesic concentration of a second anesthetic composition; processing the patient's P BIS and P MAP data using the algorithm to obtain the target hypnotic concentration and / or the target analgesic concentration of the second anesthetic composition.

The present invention relates to a pharmaceutical composition containing an etomidate derivative, a pharmaceutically acceptable salt thereof, a prodrug thereof, or an isotope derivative thereof, and a use thereof as an anesthetic, sedative and / or hypnotic drug for animals or humans. The pharmaceutical composition is a fat emulsion injection, the encapsulation efficiency of the pharmaceutical composition is stabilized at 90% or above to 98%, the particle size is small and concentrated in distribution, the content of related substances (including acid impurities and total impurities) is lower than that of an etomidate emulsion injection, and the stability, bioavailability, safety and effectiveness of the pharmaceutical composition are better. In the aspect of clinical application, compared with etomidate, the etomidate derivative has the advantages that the clinical dosage is reduced, the anesthesia, sedation and / or hypnosis duration on animals or human beings under the condition of a relatively low dosage is longer than that of an etomidate group with a relatively high dosage, the recovery time is overall better than that of the etomidate group, the adverse reaction is obviously reduced, and the etomidate derivative has a good clinical application prospect. The problems that the etomidate anesthetic is large in dosage and large in side effect are solved, and discomfort of a patient in the treatment process can be remarkably reduced.